Theralugand (lutetium (177Lu) chloride)
- Region
- 🇪🇺 EU
- Active substance
- lutetium (177Lu) chloride
- Company
- Eckert & Ziegler Radiopharma GmbH
- Status
- Authorised
- Therapeutic area
- Radionuclide Imaging
- CHMP opinion
- Thu 19 Sep 2024
- EU approval
- Fri 22 Nov 2024
- Application
- EMEA/H/C/005882
- ATC
- V10X
- Official record
- www.ema.europa.eu
Indication
Theralugand is a radiopharmaceutical precursor, and it is not intended for direct use in patients. It is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177Lu) chloride.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 EndolucinBeta Authorised · ITM Medical Isotopes GmbH
- 🇪🇺 Ilumira Authorised · Shine Europe B.V.
- 🇪🇺 Lumark Withdrawn · I.D.B. Radiopharmacy B.V.
- 🇪🇺 Lutetium (177Lu) chloride Billev (previously Illuzyce) Authorised · Billev Pharma Aps
Follow Theralugand
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.